Budesonide

Catalog No.S1286

For research use only.

Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis.

Budesonide Chemical Structure

CAS No. 51333-22-3

Selleck's Budesonide has been cited by 4 Publications

Purity & Quality Control

Choose Selective Glucocorticoid Receptor Inhibitors

Biological Activity

Description Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis.
Targets
Glucocorticoid receptor [1]
In vitro

Budesonide effectively inhibits production of eotaxin and RANTES protein although Budesonide inhibits the expression of chemokine mRNA to a variable extent in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. Budesonide inhibits both RANTES- and eotaxin promoter-driven reporter gene activity in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. Budesonide also selectively accelerates the decay of eotaxin and MCP-4 mRNA in the human bronchial epithelial cell line BEAS-2B and in primary human bronchial epithelial cells. [1] Budesonide time- and protein synthesis-dependently reduces VEGF secretion and VEGF mRNA expression in both cell types and these effects are inhibited by mifepristone (RU 486), a glucocorticoid receptor antagonist, suggesting that Budesonide reduces VEGF secretion and expression through its glucocorticoid receptor-mediated action. [2] Budesonide causes a dose-dependent, almost total, inhibition of swine dust-induced IL-6 and IL-8 release from epithelial cells and LPS-induced IL-6 and TNF-alpha from alveolar macrophages. [3]

In vivo Budesonide totally prevents the increased production of TNF-alpha, interleukin (IL)-1beta, IL-6, and monocyte chemoattractive protein (MCP)-1 after LPS challenge at both low (2.5 mg/mL/kg) and high (50 mg/mL/kg) concentrations in rats. [4] Budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9 in A/J mice. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 430.53
Formula

C25H34O6

CAS No. 51333-22-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C4C(CC3(C2(O1)C(=O)CO)C)O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05341401 Not yet recruiting Drug: Budesonide MMX|Drug: Prednisolone Ulcerative Colitis Chronic Assiut University June 2022 Phase 2|Phase 3
NCT05148312 Completed Drug: Budesonide Inhalant Product Pharmacokinetics Aquilon Pharmaceuticals S.A. November 12 2021 Phase 1
NCT04342039 Recruiting Drug: Budesonide Nasal|Other: Placebo Epigenetic Effects of Intranasal Steroids|Environmental Exposure University of British Columbia|Genome British Columbia|Johnson & Johnson Consumer Inc. (J&JCI) January 7 2021 Phase 4
NCT04663386 Terminated Drug: Budesonide-Formoterol Asthma|COPD Orion Corporation Orion Pharma December 10 2020 --

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Budesonide | Budesonide ic50 | Budesonide price | Budesonide cost | Budesonide solubility dmso | Budesonide purchase | Budesonide manufacturer | Budesonide research buy | Budesonide order | Budesonide mouse | Budesonide chemical structure | Budesonide mw | Budesonide molecular weight | Budesonide datasheet | Budesonide supplier | Budesonide in vitro | Budesonide cell line | Budesonide concentration | Budesonide nmr